Rheumatology Strong — NICE TA383 / Garrett 1994
BASDAI — Bath Ankylosing Spondylitis Disease Activity Index
6-question patient-reported outcome measuring disease activity in axial spondyloarthritis (ankylosing spondylitis). Score ≥ 4 indicates active disease — biologic eligibility threshold.
References
- Garrett S et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol. 1994.
- NICE TA383. Adalimumab, etanercept, secukinumab and certolizumab pegol for treating active ankylosing spondylitis. 2016.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Benralizumab · Anti-IL-5 receptor alpha monoclonal antibody (anti-eosinophilic biologic)
- Dupilumab (Moderate-Severe Asthma) · Anti-IL-4/IL-13 receptor alpha monoclonal antibody (type 2 inflammation biologic)
- Tezepelumab · Anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody — broad-phenotype biologic
- Rituximab (Rheumatology) · Biologic DMARD — Anti-CD20
- Guselkumab · Biologic DMARD — IL-23 Inhibitor (Anti-p19)
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.